Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ImageneBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ImageneBio's regulatory disclosures and financial reporting.
ImageneBio, Inc. completed a reverse recapitalization through a merger with Ikena Oncology that resulted in ImageneBio as the public company and produced pro forma combined financial statements giving effect as if the transactions occurred on January 1, 2024. The company divested its Non-OX40 business to SellCo for a promissory note of $8.9 million that accrues interest at 4.61% and matures by 2035 or on earlier default triggers. The filing highlights one-time pro forma adjustments including $14.9 million of share-based compensation, other merger-related cash payments (severance/retention and D&O tail) and derecognition of certain deferred offering costs. Management warns of recurring losses and negative operating cash flows that raise substantial doubt about going concern and states additional capital will be required to advance IMG-007.
IMG-007 is a non-depleting anti-OX40 monoclonal antibody in Phase 2 development for moderate-to-severe atopic dermatitis. Clinical results disclosed include a Phase 1b/2a proof-of-concept with durable activity up to 24 weeks, an EASI-75 rate of 54% by Week 16 in a 13-patient cohort, favorable tolerability (no serious adverse events reported), target-mediated PK with projected therapeutic IV doses (300–600 mg) maintaining target levels for 18 weeks and mean terminal half-life ~31–35 days. The company discloses patent filings (U.S. and international) with expected patent expiration in 2041 and notes regulatory, manufacturing, intellectual property, litigation and reimbursement risks.
ImageneBio insider ownership updated after a corporate merger. The Form 4 reports that, as part of a two-step merger, legacy Inmagene ordinary and preferred shares were converted into Issuer common stock at a fixed exchange ratio, resulting in the reporting person receiving 143,832 shares directly and an indirect interest in 971,173 shares held by Engene Inc.
The transfers arose from the merger consideration exchanged for 47,142,857 Series Seed convertible preferred shares and 318,313,306 ordinary shares of legacy Inmagene, using a conversion factor of 0.003051 common shares per legacy share. The filer disclaims beneficial ownership of Engene Inc.'s shares except for any pecuniary interest; Engene Inc.'s sole shareholder is a trust for which reporting person's family are beneficiaries. The filing notes it was submitted late due to administrative delays.
ImageneBio amended its current report to provide additional disclosure about the acquired business, Inmagene. The amendment adds Management's Discussion and Analysis for Inmagene and unaudited interim condensed financial statements covering the three- and six-month periods ended June 30, 2025 and 2024. The filing incorporates these items as Exhibits 99.3 and 99.4 and states it does not change any other previously reported items or discuss developments after the original report. The disclosure supplements the Original Report that had reported completion of the Merger.
FAQ
What is the current stock price of ImageneBio (IMA)?
What is the market cap of ImageneBio (IMA)?
